OBJECTIVES: To gain updated estimates of prevalence and incidence of RA and proportion on biological treatment in southern Sweden. METHODS: Inpatient and outpatient health care provided to residents in the southernmost county of Sweden (1.2 million inhabitants) is registered in the Skåne Health Care Register (SHCR). We identified residents aged > or = 20 years who had received a diagnosis of RA at least twice during 2003-08. Valid point prevalence estimates by 31 December 2008 were obtained by linkage to the Swedish population register, and information on biological treatment was obtained from the South Swedish Arthritis Treatment Group register. We also tested our estimates of RA occurrence in a series of sensitivity analyses to investigate the effect of altered case criteria and the uncertainty generated by clinical visits without diagnoses. RESULTS: The prevalence of RA in adults was estimated to 0.66% (women = 0.94%, men = 0.37%). The prevalence peaked at age 70-79 years (women = 2.1%, men = 1.1%) before dropping in those aged > or = 80 years. Of prevalent cases, 20% had ongoing biological treatment, a percentage that was highest in women aged 40-49 years (36%). The incidence of RA in 2008 was estimated as 50/100,000 (women = 68/100,000, men = 32/100,000). CONCLUSIONS: When compared with a previous report from southern Sweden, the prevalence of RA seems not to have declined in the last decade. The proportion of patients with ongoing biological treatment was slightly higher in women than men. SHCR data are promising additions to other methods to gain frequency estimates of clinically important disease in a timely and cost-efficient manner.
OBJECTIVES: To gain updated estimates of prevalence and incidence of RA and proportion on biological treatment in southern Sweden. METHODS: Inpatient and outpatient health care provided to residents in the southernmost county of Sweden (1.2 million inhabitants) is registered in the Skåne Health Care Register (SHCR). We identified residents aged > or = 20 years who had received a diagnosis of RA at least twice during 2003-08. Valid point prevalence estimates by 31 December 2008 were obtained by linkage to the Swedish population register, and information on biological treatment was obtained from the South Swedish Arthritis Treatment Group register. We also tested our estimates of RA occurrence in a series of sensitivity analyses to investigate the effect of altered case criteria and the uncertainty generated by clinical visits without diagnoses. RESULTS: The prevalence of RA in adults was estimated to 0.66% (women = 0.94%, men = 0.37%). The prevalence peaked at age 70-79 years (women = 2.1%, men = 1.1%) before dropping in those aged > or = 80 years. Of prevalent cases, 20% had ongoing biological treatment, a percentage that was highest in women aged 40-49 years (36%). The incidence of RA in 2008 was estimated as 50/100,000 (women = 68/100,000, men = 32/100,000). CONCLUSIONS: When compared with a previous report from southern Sweden, the prevalence of RA seems not to have declined in the last decade. The proportion of patients with ongoing biological treatment was slightly higher in women than men. SHCR data are promising additions to other methods to gain frequency estimates of clinically important disease in a timely and cost-efficient manner.
Authors: Jorit J L Meesters; Ingemar F Petersson; Stefan Bergman; Emma Haglund; Lennart T H Jacobsson; Ann Bremander Journal: Clin Rheumatol Date: 2014-06-08 Impact factor: 2.980
Authors: Katarina Sjövall; Bo Attner; Martin Englund; Thor Lithman; Dennis Noreen; Barbro Gunnars; Bibbi Thomé; Håkan Olsson; Ingemar F Petersson Journal: Support Care Cancer Date: 2011-04-10 Impact factor: 3.603
Authors: Gabriel Chodick; Howard Amital; Yoav Shalem; Ehud Kokia; Anthony D Heymann; Avi Porath; Varda Shalev Journal: PLoS Med Date: 2010-09-07 Impact factor: 11.069